Have a feature idea you'd love to see implemented?
Let us know!
ELDN Eledon Pharmaceuticals Inc
Price (delayed)
$4.26
Market cap
$254.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.18
Enterprise value
$248.24M
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring
Highlights
Eledon Pharmaceuticals's EPS has increased by 47% YoY and by 25% QoQ
The net income has grown by 39% from the previous quarter and by 31% YoY
The debt has declined by 24% since the previous quarter but it is up by 4.6% year-on-year
The quick ratio has dropped by 70% year-on-year and by 55% since the previous quarter
The company's equity fell by 17% YoY
Key stats
What are the main financial stats of ELDN
Market
Valuations
Earnings
Shares outstanding
59.74M
Market cap
$254.49M
Enterprise value
$248.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$99.95M
EBIT
-$99.95M
EBITDA
-$99.58M
Free cash flow
-$37.42M
Per share
Balance sheet
Liquidity
EPS
-$4.18
EPS diluted
-$4.18
Free cash flow per share
-$0.72
Book value per share
$1.92
Revenue per share
$0
TBVPS
$2.21
Total assets
$114.58M
Total liabilities
$38.52M
Debt
$501,000
Equity
$76.06M
Working capital
$69.02M
Debt to equity
0.01
Current ratio
6.53
Quick ratio
6.26
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-98.7%
Return on equity
-665.9%
Return on invested capital
-118.6%
Return on capital employed
-97.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELDN stock price
How has the Eledon Pharmaceuticals stock price performed over time
Intraday
-0.23%
1 week
0.95%
1 month
0.24%
1 year
140.68%
YTD
136.67%
QTD
71.08%
Financial performance
How have Eledon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.22M
Net income
-$99.95M
Gross margin
N/A
Net margin
N/A
The net income has grown by 39% from the previous quarter and by 31% YoY
The operating income is up by 38% year-on-year but it has declined by 20% since the previous quarter
Growth
What is Eledon Pharmaceuticals's growth rate over time
Valuation
What is Eledon Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eledon Pharmaceuticals's EPS has increased by 47% YoY and by 25% QoQ
The stock's price to book (P/B) is 179% more than its 5-year quarterly average of 0.8
The company's equity fell by 17% YoY
Efficiency
How efficient is Eledon Pharmaceuticals business performance
The return on invested capital has surged by 56% year-on-year and by 40% since the previous quarter
ELDN's return on assets is up by 42% since the previous quarter and by 36% year-on-year
Eledon Pharmaceuticals's return on equity has increased by 24% QoQ
Dividends
What is ELDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELDN.
Financial health
How did Eledon Pharmaceuticals financials performed over time
The total assets is 197% more than the total liabilities
Eledon Pharmaceuticals's total liabilities has plunged by 70% from the previous quarter
The current ratio has dropped by 70% year-on-year and by 55% since the previous quarter
The debt is 99% smaller than the equity
The company's debt to equity has surged by 113% QoQ
The debt has declined by 24% since the previous quarter but it is up by 4.6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.